{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Binmama S"],"funding":["Chulalongkorn University through Fundamental Fund 65","The Program Management Unit for Human Resources &amp; Institutional Development, Research, and Innovation"],"pagination":["10951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9505986"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(18)"],"pubmed_abstract":["Although the impacts of <i>Saccharomyces cerevisiae</i> on cancers are mentioned, data on its use in mice with cyclic GMP-AMP synthase deficiency (cGAS-/-) are even rarer. Here, 12 weeks of oral administration of <i>S. cerevisiae</i> protected cGAS-/- mice from azoxymethane (AOM)-induced colon cancers, partly through dysbiosis attenuation (fecal microbiome analysis). In parallel, a daily intralesional injection of a whole glucan particle (WGP; the beta-glucan extracted from <i>S. cerevisiae</i>) attenuated the growth of subcutaneous tumor using MC38 (murine colon cancer cell line) in cGAS-/- mice. Interestingly, the incubation of fluorescent-stained MC38 with several subtypes of macrophages, including M1 (using Lipopolysaccharide; LPS), M2 (IL-4), and tumor-associated macrophages (TAM; usi"],"journal":["International journal of molecular sciences"],"pubmed_title":["Beta-Glucan from <i>S. cerevisiae</i> Protected AOM-Induced Colon Cancer in cGAS-Deficient Mice Partly through Dectin-1-Manipulated Macrophage Cell Energy."],"pmcid":["PMC9505986"],"funding_grant_id":["B16F640175 and B05F640144","CUFRB65_hea [33] _040_30_21"],"pubmed_authors":["Cheibchalard T","Hiengrach P","Chindamporn A","Binmama S","Pisitkun P","Visitchanakun P","Dang CP","Somboonna N","Leelahavanichkul A"],"additional_accession":[]},"is_claimable":false,"name":"Beta-Glucan from <i>S. cerevisiae</i> Protected AOM-Induced Colon Cancer in cGAS-Deficient Mice Partly through Dectin-1-Manipulated Macrophage Cell Energy.","description":"Although the impacts of <i>Saccharomyces cerevisiae</i> on cancers are mentioned, data on its use in mice with cyclic GMP-AMP synthase deficiency (cGAS-/-) are even rarer. Here, 12 weeks of oral administration of <i>S. cerevisiae</i> protected cGAS-/- mice from azoxymethane (AOM)-induced colon cancers, partly through dysbiosis attenuation (fecal microbiome analysis). In parallel, a daily intralesional injection of a whole glucan particle (WGP; the beta-glucan extracted from <i>S. cerevisiae</i>) attenuated the growth of subcutaneous tumor using MC38 (murine colon cancer cell line) in cGAS-/- mice. Interestingly, the incubation of fluorescent-stained MC38 with several subtypes of macrophages, including M1 (using Lipopolysaccharide; LPS), M2 (IL-4), and tumor-associated macrophages (TAM; usi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-05-29T20:02:58.243Z","creation":"2025-05-29T20:02:58.243Z"},"accession":"S-EPMC9505986","cross_references":{"pubmed":["36142859"],"doi":["10.3390/ijms231810951"]}}